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ABSTRACT 
Objective: The aim of the present study leads a comparative assessment of the toxicological profile of PEGylated fourth and fifth-generation poly 
(propylene imine) dendrimers (PPI).  
Methods: 4.0G and 5.0G generations of PPI dendrimer were synthesized and PEGylated with Mono polyethylene glycol 5000 (MPEG-5000). Each 
PEGylated 4.0G and 5.0G dendrimeric generation were administered in three different doses: 2.5 mg/kg, 25 mg/kg and 250 mg/kg (i.e., low, 
intermediate and high dose) to wister rats. After the dose administration, the blood and tissue samples of wister rats were collected after 24 h and 
15 d after. All the collected samples were proceeded for hematological, biochemical and histopathological studies. 
Results: After 24 h of (250 mg/kg) dose administration PEGylated 5.0G PPI dendrimer the RBC count, hemoglobin content and WBC count were found 
7.873±0.129 mill/cmm, 13.833±0.491g/dl and 9033.33±2384.906 mill/cmm, while PEGylated 4.0G PPI dendrimer indicated RBC count, hemoglobin content 
and WBC count 8.733±0.239 mill/cmm, 14.033±0.12 g/dl and 9666.667±2567.316 mill/cmm, in blood samples as compare to RBC count 9.346±0.037 
mill/cmm, hemoglobin content 15.35±0.15 g/dl and WBC count 8500±286.675 mill/cmm of the animals of normal control group. Thus there are no 
remarkable changes (p>0.05) in RBC count, hemoglobin content and other hematological profile after 24 h in comparison of normal control group of animals. 
Similarily insignificant changes (p>0.05) in serum glutamic oxaloacetic transaminase (SGOT), serum glutamic pyruvic transaminase (SGPT), lactate 
dehydrogenase (LDH) and sections of different organs indicate inoffensive nature of both generations of PEGylated 4.0G and 5.0 G PPI dendrimers. 
Conclusion: It can be concluded that fifth-generation PPI dendrimers are more suitable as compared to fourth generation of PPI dendrimer, while 
both dendrimers are not generating any severe toxicity. 
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Carriers which are used to administer therapeutic agents into the body 
are known as drug delivery systems. The drug delivery systems 
potentiate pharmacological effects and pharmacokinetics of 
medicaments with minimum toxicity. At present, in the era of 
nanotechnology, so many attractive carriers like liposomes, 
nanoparticles, carbon nanotubes and dendrimers are available for drug 
delivery [1-3].  
Dendrimer is one of the most explored polymeric nanocarriers among 
the available polymeric nanocarriers [4, 5]. In the arena of drug delivery, 
dendrimers are stereographical polymeric architectures, lead potential 
for attraction. Dendrimers have diameter ranging from 1-10 nm with 
wide hydrophobic cavities in which the bioactive molecules are 
entrapped and provide facility for sustained and controlled drug release 
[6-8]. Dendrimers have exceptional structural properties as 
monodispersity, high density of terminal functional groups, well-defined 
globular shape and multivalency and hence, create an attraction for 
controlled as well as in targeted drug delivery systems [9, 10]. 
Dendrimers are proving their potential in the field of drug delivery as 
well as gene/DNA delivery [11-13].  
Structures of dendrimers contain three separate domains named as 
central core, branches, and peripheral functional groups. The core 
contains a single atomic group with two identical chemical 
functional units while branches nascent from the core consist 
repeated functional units at least one branch junction. These 
junction units are progressively repeated and produce a series of 
radially concentric layers known as ‘Generations’ fig. 1 [12, 14]. The 
repetition of these layers leads to consequential higher generations. 
The numbers of terminal functional groups increase exponentially 
with each subsequent generation. But many dendrimers have free 
amino groups at their terminal ends contributing to toxic behavior 
and thus limiting clinical applications of these polymers [15]. To 
improve biocompatibilities of the dendrimers, various strategic 
functionalization and other methods are employed for trapping 
terminal amino ending of these potential molecules [16, 17]. Many 
other properties like drug delivery capacity, targeting potential, 
stability, the possibility of attachment of targeting groups etc 
improve with PEGylation of dendrimers [10, 18]. 
 
 
Fig. 1: Various generations of PPI dendrimer 
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The Polypropylene imine dendrimer (PPI dendrimer) contains 
terminal amino groups and these groups increase with the increase 
in generation and ultimately lead to toxicity [19]. In this scenario, to 
potentiate biocompatibility of the PPI dendrimers, the terminal 
amino endings of different generations of dendrimer are PEGylated 
with mono polyethylene glycol 5000. On the other hand, with 
increase in generation of dendrimers, the drug loading capacity also 
increases proportionately. Thus, higher generation dendrimers can 
entrap greater amount of drug [20, 21].  
The present article investigates acute toxicities including hemolytic 
parameters, biochemical parameters and histopathological studies 
of PEGylated G4 and G5 PPI dendrimers. The outcome of this study 
will significantly contribute to selection of appropriate dendrimer 
generation in term of its toxicity as well as drug delivery behaviors. 
MATERIALS AND METHODS 
Acrylonitrile (ACN) and ethylenediamine (EDA) were purchased 
from CDH (India). Raney Nickel was purchased from Fluka (USA). 
Mono methoxy polyethylene glycol 5000 (MPEG-5000) was 
arranged from Sigma Chemicals. N,N’-dicyclohexyl carbodiimide 
(DCC), was brought from HiMedia Lab., Mumbai, India. MTT [3-(4,5-
dimethyl thiazolyl-2)-2,5 diphenyltetrazolium bromide] was 
purchased from Sigma-Aldrich (USA). Analytical grade reagents 
were purchased from Merck India Ltd. (Mumbai, India). Serum 
glutamic oxaloacetic transaminase (SGOT), Lactate dehydrogenase 
(LDH), and Serum glutamic pyruvic transaminase (SGPT) diagnostic 
kits were purchased from Sigma Chemicals. The protocol for animal 
experiment was approved by the Institutional Animal Ethics 
Committee, Nirma University Ahmedabad, India (IP/PCOL/ 
FAC/18/30).  
Synthesis of PPI dendrimers of different generations 
The different generations (3.0G, 4.0G and 5.0G)of PPI dendrimer 
were synthesized from the reported divergent method in which 
EDTA was used as inner core while acrylonitrile as branching 
moiety.[22-24] [8] The detailed synthesis is shown in fig. 2. 
  
 
Fig. 2: Schematic representation of synthesis of different generations of PPI dendrimers 
 
The acrylonitrile was added in aqueous solution of EDTA with 
double Michael addition reaction leading to formation of half-
generation of PPI dendrimer. The reaction was followed with 
exothermic addition in which temperature was raised up to 38 °C 
while 80 °C temperature was maintained during entire addition 
reaction. Then, the synthesized–CN terminated half-generation PPI 
dendrimer was subjected to heterogenous hydrogenation in the 
presence of Raney nickel as catalyst. This led to synthesis of an 
amine-terminated full generation of PPI dendrimer. The iterative 
process of addition of acrylonitrile after that hydrogenation 
produced up to 5G PPI dendrimers. 
The synthesized different generations of PPI dendrimers were 
subjected to structure elucidation using FT-IR spectroscopy by KBr 
pellets and H1-NMR spectroscopy. After that, determination of 
average particle size and polydispersity index in deionized water 
was carried out for different generations of PPI dendrimers in a 
Zetasizer (DTS Ver. 4.10, Malvern Instruments, England).  
PEGylation 
For PEGylation, Mono polyethylene glycol 5000 (MPEG-5000) was 
converted into carboxylic acid derivative then in NHS ester as per 
the given scheme of fig. 3. 
The synthesized G4 and G5 PPI dendrimers had 32 and 64 amino 
groups at their terminal ends with molecular weight 3486 and 7140 
respectively. One hundred milligram of each generation of G4 and G5 
PPI dendrimer was dissolved in double-distilled water. 
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Fig. 3: Scheme representing PEGylation of different generations of PPI dendrimers 
 
Then, the solution of activated MPEG NHS ester (0.32 mmol) was 
added in the solution of 0.01 mmol of G4 and G5 PPI dendrimers in 
dimethyl sulfoxide (DMS), stirred gently at room temperature for 5 d 
in dark condition, separately. The final products obtained were 
concentrated and lyophilized [25, 26]. The PEGylated PPI 
dendrimers were characterized using FT-IR spectroscopy and H1 
NMR spectroscopy.  
In vivo toxicity studies 
Healthy male Wistar rats of approximately equal body weight were 
received from the institutional animal house of Nirma University 
Ahmedabad, India (IP/PCOL/FAC/18/30) and kept on standard diet 
and water. The animals were divided into three groups. The group I 
and II were further divided into three subgroups according to 
protocol for administration of different doses of PEGylated PPI 
dendrimer, each subgroup comprised of three animals. The third 
group of animals served as control. PEGylated PPI dendrimers of G4 
and G5 generations, were administered in three different doses: 2.5 
mg/kg, 25 mg/kg and 250 mg/kg (i.e., low, intermediate and high 
dose) intravenously to the three groups of rats separately via tail 
vein injection. 
Haematological studies 
Various haematological parameters like Red Blood Cell (RBC) count, 
White Blood Cell (WBC) count, haematocrit (HCT) values, 
hemoglobin (Hb) percentage, and platelets count were estimated. 
Blood samples of the animals were collected after 24 hr of PPI 
dendrimer administration. All of haematological parameters were 
determined in an ABACUS 380 automatic Hematological Cell 
Counter. For estimation of different serum biochemical parameters 
like lactate dehydrogenase (LDH), serum glutamate oxaloacetate 
transaminase (SGOT), serum glutamate pyruvate transaminase 
(SGPT), the blood specimens of animals were followed for serum 
separation and estimated in Roche Autoanalyzer (UK) from the 
different estimation kits. 
Histopathological studies 
Animals were sacrificed after 24 h and after 15 d respectively for 
acute toxicity study and different organs like liver, kidney, spleen, 
lungs, and brain were studied for histopathology. For decay 
prevention, organ samples were immediately transferred in a 
fixative and the tissue was stabilized. The histological slides were 
examined under a microscope and photomicrographs were taken at 
suitable magnifications. 
Statistical analysis 
Statistical analysis was carried out by one-way ANOVA followed by 
Tukey-Kramer multiple comparison test using Graph Pad Instant 
Software (Version 7.00, Graph Pad Software, San Diego, CA, USA). 
Difference with p<0.05 was considered to be statistically significant, 
while p<0.001 was considered a very significant difference. 
RESULTS  
The synthesized different generations of PPI dendrimers were 
highly viscous, dark brownish colored liquid and freely soluble in 
water. Different generations of PPI dendrimers were purified and 
dialyzed through a cellulose dialysis membrane, having molecular 
cut off of 12 KD (Sigma chemicals, St Louis, MO, USA), characterized 
by FTIR, 1HNMR and microscopic studies. The spectroscopic data 
confirmed the synthesis of a different generation of PPI dendrimers 
(fig. 4, 5 and 6). 
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Fig. 4: IR spectra of 5.0G PPI dendrimer 
 
 
Fig. 5: NMR Spectra of 5.0G PPI dendrimer 
 
 
Fig. 6: TEM of 5.0G PPI dendrimer 
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Fig. 7: IR spectra of PEGylated 5.0G PPI dendrimer 
 
 
Fig. 8: NMR Spectra of PEGylated 5.0G PPI dendrimer 
 
The synthesized G4 and G5 PPI dendrimers were PEGylated with 
MPEG 5000. The synthesis of the final product was confirmed from 
FTIR and H1NMR spectroscopy (fig. 7 and 8). 
In vivo toxicity studies 
Hematological studies 
Different hematological parameters were evaluated for different 
generations of PEGylated PPI dendrimers at different doses with 
reference to their toxicity (table 1). The animals were administered 
with low (2.5 mg/kg), intermediate (25 mg/kg) and high (250 
mg/kg) doses of PEGlatedG4 and G5 PPI dendrimers together with 
control to evaluate acute toxicity. 
The toxic effects of PEGylated PPI dendrimers on hematological 
parameters were found to be dose-dependent. After 24 hr the blood 
samples of different groups of animals were collected and assayed 
for hematological parameters like White Blood Cell (WBC) count, 
Red Blood Cell (RBC) count, hemoglobin (Hb), hematocrit (HCT) and 
mean corpuscular hemoglobin (MCN) in an ABACUS 380 automatic 
Hematological Cell Counter. The obtained results showed a 
statistically insignificant difference in the values of hematological 
parameters in comparison to control at mild to moderate doses. At 
higher dose, PEGylated G5PPI dendrimers treated animals displayed 
significant fall in RBC count, hemoglobin content (Hb) and 
hematocrit (HCT) and increase in WBC count after 24 hr. While 
PEGlatedG4 PPI dendrimers indicated insignificant decrease in RBC 
count, Hb percentage, HCT value and platelet count at all dose levels 
but on the other side, the increase in WBC count was dose-
dependent and significantly changed with low dose to higher dose. 
All hematological parameters which were statistically significant 
tended to restore at their normal value after 15 d. The obtained data 
clearly revealed that the PEGylated PPI indicated in significant toxic 
effect on the hemopoetic system at mild to moderate doses. If any 
toxicity was observed at high dose, it was reversed in few days and 
thus the polymer did not create any permanent injury to the 
hemopoetic system with the dose limit under study. 
 
Table 1: Haematological parameters of animals treated with different doses of PEGylated G4 and G5 PPI dendrimers 




RBC Count (mill/cmm) 9.30±0.057 8.053±0.074 7.23±0.148 
WBC Count (mill/cmm) 8233.33±145 7566.67±120 7433.33±338 
Hematocrit (%)(PVC) 38.41±0.682 36.000±0.702 34.566±1.66 
Hemoglobin(g/dl) 14.666±0.44 14.233±0.145 13.933±0.233 




RBC Count (mill/cmm) 9.1±0.152 8.763±0.385 7.66±0.087 
WBC Count (mill/cmm) 8300±152.75 7366.667±88.19 7366.667±366.66 
Hematocrit (%)(PVC) 39.66±0.0754 39.533±0.202 38.166±0.12 
Hemoglobin(g/dl) 15.433±0.12 15.246±0.029 14.433±0.12 




RBC Count (mill/cmm) 9.346±0.037 8.733±0.239 7.873±0.129 
WBC Count (mill/cmm) 8500±286.675 9666.667±2567.316 9033.33±2384.906 
Hematocrit (%)(PVC) 38.896±0.472 37.353±0.978 36.6±0.935 
Hemoglobin(g/dl) 15.35±0.15 14.033±0.12 13.833±0.491 
Platelet Count (/cmm) 526333.3±8685.87 552666.7±85169.11 417000±3605.55 
Data expressed as mean±SD (n=3) 
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Estimation of serum biochemical parameters  
PEGylatedG5 and G4PPI dendrimers were assayed for serum 
biochemical study summarized in table 2. None of the PEGylated 
(G4PPI and G5PPI) at low dose (2.5 mg/kg and 25 mg/kg) exhibited 
any significant alteration in serum levels of SGOT, SGPT and LDH and 
proved their safety and biocompatibility in comparison to control. 
While at a higher dose of G5PPI dendrimers (250 mg/kg), some 
significant enhancement in SGOT and SGPT levels were seen after 24 
h of drug administration. This mild toxicity of PEGylated G5 PPI 
seems to be reversed after 15 d and the enzymes were restored at 
their normal values, concluding the healing of the tissues with time. 
 
Table 2: Serum biochemical parameters of animals treated with different doses of PEGylated G4 and G5 PPI dendrimeric carriers 
Group Days Dose (mg/kg of body weight) 
2.5 mg/kg 25 mg/kg 250 mg/kg 












Control 1 176.53±0.61 60.33±0.31 56.07±0.61 176.53±0.61 60.33±0.31 56.07±0.61 176.53±0.61 60.33±0.31 56.07±0.61 
G4 1 182.53±0.70 60.8±0.87 57.6±0.60 185.83±0.35 63.5±0.98 57.33±0.61 188.3±2.05 66.9±1.21 59.03±0.71 
 15 178.46±1.70 60.57±0.49 55.8±0.4 179.1±0.98 61.57±0.55 56.33±0.83 179.1±1.8 63.36±0.67 56.43±0.91 
G5  1 182.27±1.40 62.23±1.16 57.9±0.56 186.6±0.72 64.8±0.2 58.07±0.41 199.23±1.43 76.87±0.70 66.9±1.04 
 15 178.53±0.81 61±0.92 56±0.72 180.1±0.89 57.93±0.64 56.03±0.40 180.97±1.06 65.43±1.68 58.4±1.06 
Data expressed as mean±SD (n=3) 
 
Histopathological studies 
Histopathological studies indicated an insignificant change in tissues 
of brain and liver after 24 h and 15 d which proved the safety and 
biocompatibility of PEGylated G4 and G5 PPI dendrimeric carrier for 
these organs. Tissues of brain and liver sections of animals 
administered of high dose (250 mg/kg) of PEGylated G4 and G5 PPI 
dendrimers, displayed no signs of damage of tissues as in fig. 9, 
indicating that both generations of PEGylated PPI dendrimers are 
perfectly biocompatible with the investigated doses. 
 
 
Control group    G4 PPI group    G5 PPI group 
Liver 
    
Control group    G4 PPI group    G5 PPI group 
Brain 
Fig. 9: Photomicrograph of sections of Brain and Liver of animals of control group and animals administered with a single dose of 250 
mg/kg to PEGylated G4 and G5 PPI dendrimers after 24 h. (magnification: 400X) 
Shah et al. 




Dendrimers offer a great opportunity to researchers for fabrication of 
macromolecules with, especially tailored carrier system. The higher 
generations of dendrimers provide greater opportunity for drug 
entrapment due to availability of large cavity and offer more space for 
drug retention as compared to lower generation. The present article 
determines toxicity profile of PEGylated G4 and G5 PPI dendrimers at 
certain dose limit and compares them. For this, different generations 
include G3, G4 and G5 of PPI dendrimers were synthesized and 
characterized by FT-IR, NMR and microscopic study (see supporting 
data). The net positive charge of the PPI dendrimer depends on the 
dendrimeric peripheral amino groups. It has been directed [4] that, 
with the increase of dendrimeric generation, the transfection efficiency 
increases with a simultaneous increase in the positive charges on the 
periphery of dendrimers. After for the minimization of toxicity G4 and 
G5 PPI dendrimer were PEGylated from MPEG-5000 [18] and 
characterized with FT-IR and NMR. While [19] the toxicity of 
dendrimers enhance with its positive charges but the present report is 
suggestive of biocompatible nature of PEGylated G5 PPI dendrimers at 
administered dose limit offering better opportunity for drug targeting 
in comparison to PEGylated G4 PPI dendrimer. 
As available par data, both generations of PEGylated PPI dendrimers 
were harmless for tissues and body organs of the animals. All 
animals remained healthy, have not indicated any sign of toxicity of 
PEGylated PPI dendrimers at mild (2.5 mg/kg) and moderate (25 
mg/kg) doses during the whole study. On the other hand, some 
behavioral changes as drowsiness, anorexia and lethargy were 
noticed in case of animals with high dose (250 mg/kg) of PPI. 
The data obtained from investigation of hematological parameters in 
which WBC count of PEGylated 5.0G PPI dendrimer at 2.5 mg/kg 
7433.33±338mill/cmm at 25 mg/kg 7366.667±366.66 milli/cmm and 
at 250 mg/kg dose 9033.33±2384.906 milli/cmm similarly platelet 
count diminish from dose at 2.5 mg/kg 537000±85504.3/cmm to 
417000±3605.55/cmm at 250 mg/kg dose claimed dose-dependent 
toxicity of PEGylated PPI dendrimers over the generations. An 
insignificant fall in Hb percentage and RBC count at low of PPI 
dendrimer generations proved biocompatibility this in vivo also. 
Moreover, after 15 d of drug administration, the hematological 
parameters tend to restore at normal value with higher dose (250 
mg/kg) of PEGylated PPI dendrimers. Reversal of toxic effects after 15 
d at high dose (250 mg/kg) of PPI dendrimers proved, PPI dendrimers 
were not permanently damaged to hemopoitic system of animals. An 
insignificant increase in WBC count was observed at low and moderate 
dose of PEGylated PPI dendrimers indicating their biocompatibility as 
well as preferable in vivo acceptability. 
The serum enzyme estimation is the best quantitative marker to 
detect type and intensity of hepatocellular damage. Many times, 
foreign substances in the body lead to hepatotoxicities which 
increase the serum levels of SGPT and SGOT. On the other side, the 
appearance of distinct isoenzyme is used in clinical diagnosis of the 
damage of different tissues in the body like proportion of LDH 
associated with heart functioning. At 2.5 mg/kg and 25 mg/kg dose 
limit, PPI dendrimers were harmless to the membranes as well as 
tissues of the body organs of the animals. But, the dose-dependent 
increase of PEGylated PPI dendrimers disturbed the serum levels of 
SGOT, SGPT and LDH and marked some toxic effect on liver of 
animals. Similarly, after 15 d, the 250 mg/kg dose toxicity of 
PEGylated PPI in which after 24 h LDH 199.23±1.43 IU/l, SGOT 
76.87±0.70 IU/l and SGPT 66.9±1.04 IU/l reversed and enzymes 
were restored at their normal values LDH 180.97±1.06 IU/l, SGOT 
65.43±1.68 IU/l and SGPT 58.4±1.06 IU/l as compared to control 
group. 
The histopathological studies at a higher dose (250 mg/kg) of 
PEGylated PPI dendrimers did not indicate any sign of acute toxicity 
as well as tissue degeneration in liver and brain after 24 h and 15 d. 
Also, other organs like kidney, spleen and lungs also remained 
unaffected from PEGylated G5 PPI dendrimers at high dose. 
CONCLUSION 
Our study concluded that, at lower dose both generations PEGylated 
G4 and G5 of PPI dendrimers are biocompatible and safe for study 
on biological systems. The PEGylated G5 PPI dendrimers may be a 
better option for drug delivery as compared to PEGylated G4 PPI 
dendrimers, due to their high drug loading capacity and must be 
explored for further drug or gene targeting. However in further 
studies, the effects of fabrication of other masking groups besides 
MPEG on the periphery of PPI dendrimers is required to be explored 
on chronic toxicity study.  
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